ArticleJournal of clinical medicine2021
An Analysis of
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis.Biomolecules & therapeutics · 2026Review
- Genetic Association Study ofLife (Basel, Switzerland) · 2026Article
- Heat Shock Protein 70 Deficient Mice Exhibit Reduced Psoriasis-like Skin Inflammation.Biomedicines · 2026Article
- Association Between Inflammatory Cytokines and Systemic Inflammation Indices in Patients With Psoriasis: A Cross-Sectional Study.Health science reports · 2026Article
- Inflammatory immune mechanisms underlying the comorbidity of psoriasis and atherosclerosis: clinical implications.Frontiers in immunology · 2026Review
- Salivary Interleukins as Non-Invasive Biomarkers for Psoriasis: Advances and Challenges in Diagnosis and Monitoring.Medicina (Kaunas, Lithuania) · 2025Review
- Influence ofInternational journal of molecular sciences · 2025Article
- Exploration of Targets Potentially Linked to IL-17A Inhibitor Response in Psoriasis Using Machine Learning.Clinical, cosmetic and investigational dermatology · 2025Article
- Ameliorative effects of topical ramelteon on imiquimod-induced psoriasiform inflammation in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Inflammatory Cytokines and Clinical Outcome Following Biological Therapy in Adult Bio-Naïve Psoriasis Patients.Current issues in molecular biology · 2024Article
- Novel effect of topical Roquinimex and its combination with Clobetasol on an imiquimod-induced model of psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Article
- IL-23/IL-17 immune axis mediates the imiquimod-induced psoriatic inflammation by activating ACT1/TRAF6/TAK1/NF-κB pathway in macrophages and keratinocytes.The Kaohsiung journal of medical sciences · 2023Article
- Association between psoriasis and thyroid function: results from the Brazilian Longitudinal Study of Adults Health (ELSA-Brasil).Archives of endocrinology and metabolism · 2023Article
- Abnormalities of Sphingolipids Metabolic Pathways in the Pathogenesis of Psoriasis.Metabolites · 2023Review
- The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions.Frontiers in immunology · 2023Review
- Inhibition of Key Glycolytic Enzyme Hexokinase 2 Ameliorates Psoriasiform Inflammation in vitro and in vivo.Clinical, cosmetic and investigational dermatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Being one of the most common dermatological inflammatory disorders, psoriasis is a frequent subject of research. It is considered to be a T cell-dependent immune disease whose pathogenesis is influenced by cytokines, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.